On August 25, 2026, InvestingPro released a curated shortlist of five FTSE 250 companies identified through specific health and valuation metrics. The selection, which includes names like Wise and GSK, highlights stocks trading significantly below their estimated fair value.
The Wise inclusion and the shift toward growth
InvestingPro's latest FTSE 250 shortlist introduces a notable departure from traditional income-focused lists by including the high-growth firm Wise. Unlike the other four selections, Wise does not offer a dividend, instead presenting a price-earnings multiple of approximately 27. this inclusion signals a strategic pivot in the screen's composition, moving away from a pure value play toward a hybrid model that captures cross-border payment volume growth.
This shift suggests that the current market environment is encouraging a blend of quality and growth signals rather than a singular focus on yield. by including a no-dividend profile alongside established dividend payers, the screen acknowledges that "value" can be found in future expansion as much as in current cash distributions.
GSK’s 70% upside and the oncology pipeline gamble
The pharmaceutical giant GSK stands out in the report due to a massive projected upside of nearly 70%. As reported by InvestingPro, this significant gap between market price and fair value is heavily contingent on the successful development of its oncology and HIV drug pipelines. While GSK offers a defensive 3.5% dividend yield and a modest 15-point price-earnings multiple, the scale of the projected upside makes it a high-stakes play on clinical success.
Investors must weigh the stability of a pharmaceutical giant against the volatility of drug development. The upside is not a market forecast but a gap between current prices and model-based estimates, meaning the 70% figure is only as reliable as the projected success of those specific medical pipelines.
Private market exposure in Intermediate Capital and 3i Group
Investors looking at private-equity-oriented firms like Intermediate Capital and 3i Group face a different set of risks. Intermediate Capital, which carries a 4.3% yield and an 11-point price-earnings multiple, is inherently tied to the volatility of private-market assets. Similarly, 3i Group trades at a low 5.6-point price-earnings multiple and pays a dividend of just under 3%, but its valuation comes with a significant caveat.
According to the InvestingPro report, the model flagged a low confidence rating for 3i Group's fair-value estimate. This suggests that the reported upside for private-equity-heavy houses should be treated with more skepticism than the more transparently traded sectors.
The sustainability of MONY’s 6% dividend yield
Small-cap firm MONY presents a compelling case for income-seekers with a dividend yield exceeding 6% and a 12-point price-earnings ratio. However , the high yield on a small-cap entity often serrves as a double-edged sword. While it attracts yield-hungry investors,it can also reflect market skepticism regarding a company's ability to maintain such payouts after accounting for necessary capital expenditures.
The uncertainty behind 3i Group's low-confidence rating
Several critical factors remain unverified by the current data provided in the shortlist. First, the specific drivers behind the "low confidence" flag for 3i Group remain opaque—investors are left to wonder if the uncertainty stems from asset volatility or data gaps. Second, while the report mentions GSK's drug pipelines, it does not provide the specific clinical trial timelines required to validate the 70% upside. Finally, the sustainability of MONY's 6% yield remains an unaddressed risk that could impact real income for small-cap investors.
Comments 0